Planning for the next pandemic of influenza

Reviews in Medical Virology

Volumn 11, Issue 1, 2001, Pages 59-70

  Gust, Ian D ^a,b   Hampson, Alan W ^a   Lavanchy, Daniel ^a  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE;

ADAPTATION; ECONOMIC ASPECT; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH SURVEY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MORTALITY; PRACTICE GUIDELINE; REVIEW; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; PRACTICE GUIDELINES; VACCINATION; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 0035150829     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.301     Document Type: Review

References (90)

1. Clinical features of influenza
2. Impact of atmospheric dispersion and transport of viral aerosols on the epidemiology of influenza
3. Interpandemic influenza in the Houston area, 1974-76
4. Introduction to pandemic influenza through history
5. The chronicle of influenza epidemics
6. An influenza epicentre?
7. Influenza vaccines: A main problem in control of pandemics
8. Weekly excess death rates from influenza and pneumonia, and from other causes. Monograph No.10, 1918-51
9. Influenza vaccine and inoculation
10. Bacteriology and histopathology of the respiratory tract and lungs in fatal Asian influenza
11. Pathology: Broad aspects of the pathology and pathogenesis of human influenza
12. Influenza. A survey of the last 50 years in the light of modern work on the virus of epidemic influenza
13. Influenza in New Jersey in 1976: Isolations of influenza A/New Jersey/76 virus at Fort Dix
14. Swine influenza A at Fort Dix, New Jersey (January-February 1976). I. Case finding and clinical study of cases
15. Human influenza virus A/ HongKong/156/97 (H5N1) infection
16. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus
17. Experience with vaccination against influenza in the spring of 1947
18. The influenza programme of WHO
19. WHO influenza surveillance
20. Recommendation for the composition of influenza virus vaccines for use in 1999
21. Global influenza surveillance: Tracking a moving target in a rapidly changing world
22. Surveillance for pandemic influenza
23. Influenza B and influenza C viruses
24. Epidemiology of influenza C virus in man: Multiple evolutionary lineages and low rate of change
25. Characterization of a novel influenza hemagglutinin, H15: Criteria for determination of influenza A subtypes
26. Evolution and ecology of influenza A viruses
27. Antigenic variation in influenza virus. Biology and chemistry
28. Genes and proteins of the influenza viruses
29. Molecular aspects of the epidemiology of virus disease
30. Epidemiologic implications of changes in the influenza virus genome
31. Source for influenza pandemics
32. Recombinant viruses obtained from double infections with the influenza A viruses MEL and NEURO-WS
33. Origin of the pandemic 1957 H2 influenza A virus and the persistence of its possible progenitors in the avian reservoir
34. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts
35. A practical method for field diagnosis of swine disease
36. Epidemic influenza: A virus disease
37. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential
38. Ecology of influenza: Framework for a global WHO programme
39. Pandemic versus epidemic influenza mortality: A pattern of changing age distribution
40. Age and sex incidence of influenza and pneumonia morbidity and mortality in the epidemic of 1928-29 with comparative data for the epidemic of 1918-19
41. Observations on excess mortality associated with epidemic influenza
42. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989
43. Influenza A pandemics of the 20th century with special reference to 1918: Virology, pathology and epidemiology
44. Characterization of the 1918 'Spanish' influenza virus neuraminidase gene
45. Origin and evolution of the 1918 'Spanish' influenza virus hemagglutinin gene
46. Emerging infections: Pandemic influenza
47. The mechanism of spread of Asian influenza
48. The economic impact of pandemic influenza in the United States: Priorities for intervention
49. Influenza vaccination in 29 countries: An update to 1997
50. New approaches to influenza chemotherapy. Neuraminidase inhibitors
51. Neuraminidase inhibitors for treatment of influenza A and B infections
52. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
53. Reactogenicity and immunogenicity of bivalent influenza vaccine in one- And two-dose trials in children: A summary
54. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months
55. Adverse reactions to influenza vaccine in elderly people: Randomised double blind placebo controlled trial
56. Trials of influenza A/New Jersey/76 virus vaccine in normal children: An overview of age-related antigenicity and reactogenicity
57. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children - A multicentered evaluation of dosage and safety
58. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
59. Influenza virus neuraminidase inhibitors
60. Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors
61. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies
62. Zanamivir in the prevention of influenza among healthy adults
63. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
64. Design of aromatic inhibitors of influenza virus neuraminidase
65. Pandemic influenza: Confronting a reemergent threat. The 1976 experience
66. The swine flu vaccine program
67. An epidemiologic and clinical evaluation of Guillain-Barre syndrome reported in association with the administration of swine influenza vaccines
68. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines
69. The Canadian influenza decision, 1976
70. A pandemic warning?
71. Molecular aspects of avian influenza (H5N1) viruses isolated from humans
72. Poultry and the influenza H5N1 outbreak in HongKong, 1997: Abridged chronology and virus isolation
73. Human influenza A H5N1 virus related to a highly pathogenic avian influenza
74. Update: Isolation of avian influenza A(H5N1) viruses from humans - Hong Kong, 1997-1998
75. Risk of influenza A(H5N1) infection among health care workers exposed to patients with influenza A(H5N1), Hong Kong
76. Epidemiology of Asian Influenza. (Paper presented at International Conference). No. 2. USA
77. Origin and progress of the 1968-69 Hong Kong influenza epidemic
78. Laboratory containment for influenza A H5N1 virus: Level 2, level 3, or level 3+?
79. Some problems in the Standardization and control of influenza vaccine in 1957
80. Production and testing in the USA of influenza virus vaccine made from the Hong Kong variant in 1968-69
81. Influenza A H9N2: Aspects of laboratory diagnosis
82. Molecular characterization of H9N2 influenza viruses: Were they the donors of the 'internal' genes of H5N1 viruses in Hong Kong?
83. Vaccine manufacture at the time of a pandemic influenza
84. Chronicle of influenza pandemics
85. Influenza A virus recycling revisited